{"success":true,"data":{"pressRelease":{"id":"133181","rtpr_id":"nGNX9HWGx5","ticker":"IBIO","exchange":"NASDAQ","all_tickers":["IBIO"],"title":"iBio to Participate in the 2026 Wells Fargo Annual Healthcare Conference","author":"Globe Newswire","published_at":"2026-09-01T20:30:00.183Z","article_body":"SAN DIEGO, Sept. 01, 2026 (GLOBE NEWSWIRE) -- iBio, Inc. (NASDAQ: IBIO), a\nclinical-stage biotechnology company developing long-acting antibody\ntherapeutics for obesity, cardiometabolic and cardiopulmonary diseases, today\nannounced that it will participate in the Wells Fargo 21st Annual Healthcare\nConference, taking place September 8-10, 2026, in Boston.\n\nMartin Brenner, DVM, Ph.D., Chief Executive Officer and Chief Scientific\nOfficer of iBio, will participate in a fireside chat on Tuesday, September 8,\nat 4:30 p.m. ET.\n\nA livestream of the event can be accessed here\n(https://www.globenewswire.com/Tracker?data=EXR1dPqNlbNnTC_hqXRR0YtHTD2gpp1P2XTzEH_Ym-lKaNKL1OYvC-moZMutD8iQUOr1Rzc6jeXXZ77VieyBjsoTFLoTALjt-dkqkn8Wwz_R-4UnOJRQ0vtT2IjCIAsk9coW3Rm-CJal9hY1Yu_NPCZV7M8L3i64wBSxqgYBb61ktQUpc44oQ4YHc8ExWfJP4rSMzJ3zw3xAsBSE50_1jjB964qdBx_33iq0tAJW94A5EN5VAAEgJuYEszP0KXjyg9jtUD5xidKM3aOI2YUmgMJ5DFhK-ynhMKEOpyE7X_tzWohlMFJPs6AnmN8IODHYwlNNSMrVIcJud_l7Qvbs__VqAyzYTHnwxsV59xx70TFCJ9ez1ZFMJd4L6ZdhRJjwP1IgBHSzOZhDR82Jp1Sm9grEG-TmY9Fb5FRZqVR7oQRKt3sjp_r3FpEBvTvE8n1D3Qh3fdh36FYlTMrRtZkDB2GC-OZaeY5xRG6ajm-hUy-PE6oqM4qZRZE-VpDFm363ACsMw8wr6jHbweuuR2wsZ_98jdu7rZBJRLQ9HS4n-H4IR1DPct0Z7kCNoqL1Gy1LjoJnBFqQreguWCtrGlRGSCka1lIhmpBC5iw-IgaiH4dkaOmHsXX0mCo9tIIVoumYOPhK0vYuj0F-e1szMnvT_C-nlK-XQnxVT71xvsy_7SI=),\nand a replay of the presentation webcast will be available on the Investor\nRelations section of the iBio website for 90 days following the event.\n\nFelipe Duran, iBio’s Chief Financial Officer, will be available with Dr.\nBrenner for one-on-one investor meetings during the conference. To request a\nmeeting with Dr. Brenner or Mr. Duran at either conference, please contact\nir@ibioinc.com.\n\nAbout iBio, Inc.\n\niBio (Nasdaq: IBIO) is a clinical-stage biotechnology developing long-acting\nantibody therapeutics for obesity, cardiometabolic and cardiopulmonary\ndiseases, cancer, and other hard-to-treat diseases. Combining advanced\nantibody engineering with AI-driven discovery, iBio is advancing a\ndifferentiated pipeline designed to deliver sustained therapeutic effects and\naddress significant unmet medical needs. iBio’s mission is to transform drug\ndiscovery, accelerate development timelines, and unlock new possibilities in\nprecision medicine.\n\nFor more information, visit www.ibioinc.com or follow us on LinkedIn\n(https://www.globenewswire.com/Tracker?data=ZQTkxyGg9o_0dztwYgJCj9u3_naEr1EaCMLpeFZLKU5QyK0G6ESINSAwiLm1Mc-SkdYrmsLLx9uLHv0tYIYIl3N__8M3JkfzO12DvqdmDacjY1RPDmVaeMZanB_1jp182CliMaig--z5htAEjTgAdHXK_7wAEDHa0MP_o2Pb4y8YaS1KkFHURMdEHv-m8iKi1y0NUxTWnzfYq18pHxnssuzopDdCZr2FL7chkdfyVSyMmozIk9tRG8wz2D-SiHx_dioJfRV3CIXqPlqwPNAicqbxgORJSFNNUO_hC1AK_AbGLtrjg_2JA9yiN9RC0tY7j5ke8HbtoeL-QrM8e7gFOPoQ6zox34KW4qvMvTsG7x5LHtdmDkERxj55UVDQorBr2Jmquw8aiXHGDkVqVcVHva1aQ2CsuOAd6VGhnW9qXvXeso_X80eaZfoq3w-VD93farULXAguNVVK8LFgyicDilOyvAPLYc_Cmz8R_-9wqycgxCom-DwCerEdl7OndxrBiMg6haB1YQr10XYkUy8lmGiaihov5rnQ1vlGd1_PmdrQrH2qLGizDYqBZyvZ6seSq97tVWgCPJpuURNlzCQlpVsupM1uHnm1jlyX_ZuiBi1GO74bJsjsH9iBEb877H84pCC6wAdHyuHCHqHa_QH4JYbxbrSxX51DQMKAV4e6alwzYQcCGOQVnWidsUOGJaYuc6-2sj1efKc-d8-U3h-LR0Jy6VrKWbrj5y5VJ9X3oNdqDHUpPtJ36tvuKIcveXlDGMkF8sHlAAtTvM9CJmugbgHxlwDhKVuft_AlbtB3lzIF1cgky4UJaG91VEdD8u9c_OavivwmMdhMxLqGDhlID-JfZ1Q-VjIGQJwhBrgwJVbjuDSVxA1qOGmY-mVOtT4hG69r_QksP3UOsYnhNOLwMIrVOdOQDwKp8YOuDl-cZDZxGqyDZR465JdiG3TexpegRd2zbj3vxLtdFbZ4CfHcbPzz6xJ5PTDKuJeIY4t-0bGo7lCVGv-Fm0wLMWp2nF8a6JQcuqpGyZMnhyAuOgyNwH5EPCvP9yU8YXY26lECXbdOsg6mLo62sXQatKtMJSQPMMPlCgIkONpv560yXdUAV1ztNsS9-tWUg-Scq0lTBCE=).\n\nContact:\n\niBio, Inc.\nInvestor Relations\nir@ibioinc.com\n\nIgnacio Guerrero-Ros, Ph.D., or David Schull\nRusso Partners, LLC\nIgnacio.guerrero-ros@russopartnersllc.com\n\n(https://www.globenewswire.com/Tracker?data=DQhVZegLO_ZadlC2HfJ3kYVpPekdFRjwBT0FFLkw-YuugpoVnFvTeMPoXYwZiTK_DEWNNQUuogsdVbwOy_-1MtwriruFfz4eri6i-3jjvE8HpFwQ4AQZsEy3bMPkYrh68g7hDv-z5kgHVcrXCvEHDCvBTsbcdoZTgfkPe9PT3e-wyoY8_gZAQwWyok3ySTN_VHAbrerPmGTLTCj8dSsJx5p72Uh4ec5hnp4KBxdKkqcEaPW3S3SCAGhfYsTFB4swObQAdhg_MJphDvIs0_AlzO7ruCyoeGHym9H9Jjz9ih3hrcafx_0EBHfwVG0jgNFeAQ6Q7f8Mc2AxQy0YmYEvOvoAYQx_LYyl8msIw9p38K5Bt4Z7FrszfR8XXA417I2qawNf_t2csybxiOmpP2uwrtedfOXPOFbyGcfzIII9BZr-hfG2T-M1zX2Shn9b_7-bGQMLRWR_mkzdx85yZ3cqtntgG-oGfsXK3lvK7OsWjdtsCiOGoZfI5C8-AOa_AiF2ZgiTdf7JIgz9Dpb4pYAEtUQsG37D3hzXTD5ZlWu1_b4=)David.schull@russopartnersllc.com\n\n(https://www.globenewswire.com/Tracker?data=HrVNL-639fVfaW_cTMkSI3sQ__wRg6wyDWx4r9z5piOihksH6IiHebyuTc2OTR1ULKZYTWmcrJdARv4tpAIdRhTOHPrqk_CI--XhjDymK740regFdvZwbFri6AoIJq6vDE6SixjFsgR25mEoZnHuDN2heYRVQvK2yhzHZQxtlHDxUDDU7N9dO_q4xBl3toLsc9ndce8W-HFGR1HFkQL-tNs25iLgndIv92wceoaPhrf6G7WYktXmRQxOrOb035CgyKGGzhl93L8RMkLSD7WFR38O521WjJTRYE1TzpNwHrZl7sJdJRjOIy2IMwz4ntPpcKzAZbLxzn9cT7kjVjoZ2r5wiahk5G5x0T4MDqqT5BEawIXy4Ig2iXBjYe7Qm8385FYWxfW-HMcJKNsVp_qLMoOoPgo7NEobnJOzsaOkRYy_VqNgv9fgeLUVazo5ObROf1KlVMeKvze8iFP5l3lU9AF1OR5ciKi8gjl4J4Ka4ZHLSm43DVG6CPiefMkl5iPD)(858)\n717-2310 or (646) 942-5604\n\n(https://www.globenewswire.com/NewsRoom/AttachmentNg/c472b1f4-0d21-4a83-b703-3214f1faebbc)\n\n\n\nGlobeNewswire, Inc. 2026","article_body_html":"","raw_payload":{"data":{"id":"nGNX9HWGx5","title":"iBio to Participate in the 2026 Wells Fargo Annual Healthcare Conference","author":"Globe Newswire","ticker":"IBIO","created":"2026-09-01T20:30:00.183Z","tickers":["IBIO"],"exchange":"NASDAQ","article_body":"SAN DIEGO, Sept. 01, 2026 (GLOBE NEWSWIRE) -- iBio, Inc. (NASDAQ: IBIO), a\nclinical-stage biotechnology company developing long-acting antibody\ntherapeutics for obesity, cardiometabolic and cardiopulmonary diseases, today\nannounced that it will participate in the Wells Fargo 21st Annual Healthcare\nConference, taking place September 8-10, 2026, in Boston.\n\nMartin Brenner, DVM, Ph.D., Chief Executive Officer and Chief Scientific\nOfficer of iBio, will participate in a fireside chat on Tuesday, September 8,\nat 4:30 p.m. ET.\n\nA livestream of the event can be accessed here\n(https://www.globenewswire.com/Tracker?data=EXR1dPqNlbNnTC_hqXRR0YtHTD2gpp1P2XTzEH_Ym-lKaNKL1OYvC-moZMutD8iQUOr1Rzc6jeXXZ77VieyBjsoTFLoTALjt-dkqkn8Wwz_R-4UnOJRQ0vtT2IjCIAsk9coW3Rm-CJal9hY1Yu_NPCZV7M8L3i64wBSxqgYBb61ktQUpc44oQ4YHc8ExWfJP4rSMzJ3zw3xAsBSE50_1jjB964qdBx_33iq0tAJW94A5EN5VAAEgJuYEszP0KXjyg9jtUD5xidKM3aOI2YUmgMJ5DFhK-ynhMKEOpyE7X_tzWohlMFJPs6AnmN8IODHYwlNNSMrVIcJud_l7Qvbs__VqAyzYTHnwxsV59xx70TFCJ9ez1ZFMJd4L6ZdhRJjwP1IgBHSzOZhDR82Jp1Sm9grEG-TmY9Fb5FRZqVR7oQRKt3sjp_r3FpEBvTvE8n1D3Qh3fdh36FYlTMrRtZkDB2GC-OZaeY5xRG6ajm-hUy-PE6oqM4qZRZE-VpDFm363ACsMw8wr6jHbweuuR2wsZ_98jdu7rZBJRLQ9HS4n-H4IR1DPct0Z7kCNoqL1Gy1LjoJnBFqQreguWCtrGlRGSCka1lIhmpBC5iw-IgaiH4dkaOmHsXX0mCo9tIIVoumYOPhK0vYuj0F-e1szMnvT_C-nlK-XQnxVT71xvsy_7SI=),\nand a replay of the presentation webcast will be available on the Investor\nRelations section of the iBio website for 90 days following the event.\n\nFelipe Duran, iBio’s Chief Financial Officer, will be available with Dr.\nBrenner for one-on-one investor meetings during the conference. To request a\nmeeting with Dr. Brenner or Mr. Duran at either conference, please contact\nir@ibioinc.com.\n\nAbout iBio, Inc.\n\niBio (Nasdaq: IBIO) is a clinical-stage biotechnology developing long-acting\nantibody therapeutics for obesity, cardiometabolic and cardiopulmonary\ndiseases, cancer, and other hard-to-treat diseases. Combining advanced\nantibody engineering with AI-driven discovery, iBio is advancing a\ndifferentiated pipeline designed to deliver sustained therapeutic effects and\naddress significant unmet medical needs. iBio’s mission is to transform drug\ndiscovery, accelerate development timelines, and unlock new possibilities in\nprecision medicine.\n\nFor more information, visit www.ibioinc.com or follow us on LinkedIn\n(https://www.globenewswire.com/Tracker?data=ZQTkxyGg9o_0dztwYgJCj9u3_naEr1EaCMLpeFZLKU5QyK0G6ESINSAwiLm1Mc-SkdYrmsLLx9uLHv0tYIYIl3N__8M3JkfzO12DvqdmDacjY1RPDmVaeMZanB_1jp182CliMaig--z5htAEjTgAdHXK_7wAEDHa0MP_o2Pb4y8YaS1KkFHURMdEHv-m8iKi1y0NUxTWnzfYq18pHxnssuzopDdCZr2FL7chkdfyVSyMmozIk9tRG8wz2D-SiHx_dioJfRV3CIXqPlqwPNAicqbxgORJSFNNUO_hC1AK_AbGLtrjg_2JA9yiN9RC0tY7j5ke8HbtoeL-QrM8e7gFOPoQ6zox34KW4qvMvTsG7x5LHtdmDkERxj55UVDQorBr2Jmquw8aiXHGDkVqVcVHva1aQ2CsuOAd6VGhnW9qXvXeso_X80eaZfoq3w-VD93farULXAguNVVK8LFgyicDilOyvAPLYc_Cmz8R_-9wqycgxCom-DwCerEdl7OndxrBiMg6haB1YQr10XYkUy8lmGiaihov5rnQ1vlGd1_PmdrQrH2qLGizDYqBZyvZ6seSq97tVWgCPJpuURNlzCQlpVsupM1uHnm1jlyX_ZuiBi1GO74bJsjsH9iBEb877H84pCC6wAdHyuHCHqHa_QH4JYbxbrSxX51DQMKAV4e6alwzYQcCGOQVnWidsUOGJaYuc6-2sj1efKc-d8-U3h-LR0Jy6VrKWbrj5y5VJ9X3oNdqDHUpPtJ36tvuKIcveXlDGMkF8sHlAAtTvM9CJmugbgHxlwDhKVuft_AlbtB3lzIF1cgky4UJaG91VEdD8u9c_OavivwmMdhMxLqGDhlID-JfZ1Q-VjIGQJwhBrgwJVbjuDSVxA1qOGmY-mVOtT4hG69r_QksP3UOsYnhNOLwMIrVOdOQDwKp8YOuDl-cZDZxGqyDZR465JdiG3TexpegRd2zbj3vxLtdFbZ4CfHcbPzz6xJ5PTDKuJeIY4t-0bGo7lCVGv-Fm0wLMWp2nF8a6JQcuqpGyZMnhyAuOgyNwH5EPCvP9yU8YXY26lECXbdOsg6mLo62sXQatKtMJSQPMMPlCgIkONpv560yXdUAV1ztNsS9-tWUg-Scq0lTBCE=).\n\nContact:\n\niBio, Inc.\nInvestor Relations\nir@ibioinc.com\n\nIgnacio Guerrero-Ros, Ph.D., or David Schull\nRusso Partners, LLC\nIgnacio.guerrero-ros@russopartnersllc.com\n\n(https://www.globenewswire.com/Tracker?data=DQhVZegLO_ZadlC2HfJ3kYVpPekdFRjwBT0FFLkw-YuugpoVnFvTeMPoXYwZiTK_DEWNNQUuogsdVbwOy_-1MtwriruFfz4eri6i-3jjvE8HpFwQ4AQZsEy3bMPkYrh68g7hDv-z5kgHVcrXCvEHDCvBTsbcdoZTgfkPe9PT3e-wyoY8_gZAQwWyok3ySTN_VHAbrerPmGTLTCj8dSsJx5p72Uh4ec5hnp4KBxdKkqcEaPW3S3SCAGhfYsTFB4swObQAdhg_MJphDvIs0_AlzO7ruCyoeGHym9H9Jjz9ih3hrcafx_0EBHfwVG0jgNFeAQ6Q7f8Mc2AxQy0YmYEvOvoAYQx_LYyl8msIw9p38K5Bt4Z7FrszfR8XXA417I2qawNf_t2csybxiOmpP2uwrtedfOXPOFbyGcfzIII9BZr-hfG2T-M1zX2Shn9b_7-bGQMLRWR_mkzdx85yZ3cqtntgG-oGfsXK3lvK7OsWjdtsCiOGoZfI5C8-AOa_AiF2ZgiTdf7JIgz9Dpb4pYAEtUQsG37D3hzXTD5ZlWu1_b4=)David.schull@russopartnersllc.com\n\n(https://www.globenewswire.com/Tracker?data=HrVNL-639fVfaW_cTMkSI3sQ__wRg6wyDWx4r9z5piOihksH6IiHebyuTc2OTR1ULKZYTWmcrJdARv4tpAIdRhTOHPrqk_CI--XhjDymK740regFdvZwbFri6AoIJq6vDE6SixjFsgR25mEoZnHuDN2heYRVQvK2yhzHZQxtlHDxUDDU7N9dO_q4xBl3toLsc9ndce8W-HFGR1HFkQL-tNs25iLgndIv92wceoaPhrf6G7WYktXmRQxOrOb035CgyKGGzhl93L8RMkLSD7WFR38O521WjJTRYE1TzpNwHrZl7sJdJRjOIy2IMwz4ntPpcKzAZbLxzn9cT7kjVjoZ2r5wiahk5G5x0T4MDqqT5BEawIXy4Ig2iXBjYe7Qm8385FYWxfW-HMcJKNsVp_qLMoOoPgo7NEobnJOzsaOkRYy_VqNgv9fgeLUVazo5ObROf1KlVMeKvze8iFP5l3lU9AF1OR5ciKi8gjl4J4Ka4ZHLSm43DVG6CPiefMkl5iPD)(858)\n717-2310 or (646) 942-5604\n\n(https://www.globenewswire.com/NewsRoom/AttachmentNg/c472b1f4-0d21-4a83-b703-3214f1faebbc)\n\n\n\nGlobeNewswire, Inc. 2026"},"type":"article","timestamp":"2026-09-01T20:30:00.223840358Z","server_sent_at_ms":1788294600223},"received_at":"2026-09-01T20:30:00.432Z","source_url":"https://www.globenewswire.com/news-release/2026/09/01/3354626/0/en/ibio-to-participate-in-the-2026-wells-fargo-annual-healthcare-conference.html"},"analysis":{"id":"122072","press_release_id":"133181","analysis_json":{"industry":{"label":"Biotechnology","sector":"Health Care"},"redFlags":[],"eventType":"operations_update","narrative":"iBio, Inc. announced its participation in the Wells Fargo 21st Annual Healthcare Conference, scheduled for September 8-10, 2026, in Boston.\n\nCEO Martin Brenner will host a fireside chat on September 8 at 4:30 p.m. ET, while CFO Felipe Duran will be available for one-on-one investor meetings.\n\nA livestream of the presentation will be available, with a replay accessible on the company's Investor Relations website for 90 days following the event.","sentiment":"neutral","agentHooks":{"shouldPost":false,"suggestedAngle":"Investor roadshow activity only."},"keyFigures":null,"quotedText":"","namedEntities":{"people":[{"name":"Martin Brenner","role":"CEO and Chief Scientific Officer"},{"name":"Felipe Duran","role":"CFO"}],"products":[],"companies":[{"name":"iBio, Inc.","ticker":"IBIO"},{"name":"Wells Fargo","relationship":"conference organizer"}],"dollarAmounts":[]},"materialImpact":{"score":1,"reasoning":"Routine announcement of conference participation with no material financial or clinical updates disclosed."},"tickerRelevance":{"others":[],"primary":"IBIO"},"globalImportance":5,"audienceRelevance":5,"eventTypeSecondary":[],"importanceComponents":{"tickerTier":"micro-cap","eventGravity":"conference_announcement"}},"event_type":"operations_update","event_type_secondary":null,"sentiment":"neutral","material_impact_score":1,"narrative":"iBio, Inc. announced its participation in the Wells Fargo 21st Annual Healthcare Conference, scheduled for September 8-10, 2026, in Boston.\n\nCEO Martin Brenner will host a fireside chat on September 8 at 4:30 p.m. ET, while CFO Felipe Duran will be available for one-on-one investor meetings.\n\nA livestream of the presentation will be available, with a replay accessible on the company's Investor Relations website for 90 days following the event.","key_figures":null,"named_entities":{"people":[{"name":"Martin Brenner","role":"CEO and Chief Scientific Officer"},{"name":"Felipe Duran","role":"CFO"}],"products":[],"companies":[{"name":"iBio, Inc.","ticker":"IBIO"},{"name":"Wells Fargo","relationship":"conference organizer"}],"dollarAmounts":[]},"model_name":"glm-4.7","prompt_hash":"sha256:727b4b9429a443af","schema_hash":"sha256:05005c02d9cffac9","created_at":"2026-09-01T21:09:24.420Z","global_importance":5,"audience_relevance":5,"importance_components":{"tickerTier":"micro-cap","eventGravity":"conference_announcement"}},"durationMs":56580,"modelName":"glm-4.7"}}